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Influenza virus, a negative strand RNA virus, cannibalizes host cell, capped RNA polymerase II transcripts in the nucleus
via a process termed ‘‘cap-snatching.’’ The viral transcriptase enzyme, which is composed of a complex of the three viral
polymerase (P) proteins, contains a cap-dependent endonuclease that cleaves capped cellular RNAs in the nucleus 10–13
nucleotides from their 5* ends. The resulting capped RNA fragments are required as primers for the initiation of viral mRNA
synthesis. In the 18 years since the discovery of ‘‘cap-snatching’’ it has not been determined how the viral transcriptase
exhibits selectivity and ‘‘snatches’’ caps from cellular, but not viral, mRNAs. Here we elucidate the surprising mechanism
of this selectivity: the complex of the same three viral P proteins that catalyzes ‘‘cap-snatching’’ is also responsible for
selectivity protecting the 5* ends of viral, but not cellular, mRNAs from ‘‘cap-snatching.’’ The viral P protein complex is able
to acquire these two very different functions because this complex lacks any detectable activity unless it binds to one or
more specific RNA sequences. Here we demonstrate that the viral P protein complex binds to the common sequence in
all the viral mRNAs that is immediately 3* to the 5* sequence that is ‘‘snatched’’ from host cell RNAs. This binding activates
the cap-binding activity of the P protein complex, thereby enhancing its binding to the capped viral mRNA. We show that
these P protein complexes protect the 5* ends of viral mRNAs from endonucleolytic cleavage by the viral transcriptase,
whereas the 5* ends of nonviral mRNAs are not protected. q 1996 Academic Press, Inc.
transcriptase exhibits selectivity by ‘‘snatching’’ caps fromViruses are obligate parasites that exploit host cell
cellular, but not viral, mRNAs (3). This selectivity is essen-functions for their replication. One of the most dramatic
tial because if the 5* ends of viral mRNAs were alsoexamples of this exploitation is the process termed ‘‘cap-
cleaved and used as primers, then net synthesis of viralsnatching’’ that is carried out by influenza virus (1–3).
mRNAs would not occur. We have now succeeded inThis negative-strand RNA virus cannibalizes host cell,
elucidating the mechanism of this selectivity. Amazingly,capped RNA polymerase II transcripts in the nucleus to
the same three viral polymerase (P) proteins (PB1, PB2,supply primers that are needed for the initiation of viral
PA) that constitute the viral transcriptase enzyme (3) thatmRNA synthesis. The viral transcriptase enzyme complex
cleaves all capped RNAs are also responsible for selec-contains a cap-dependent endonuclease that cleaves
tively protecting the 5* ends of viral, but not cellular,capped cellular RNAs in the nucleus 10–13 nucleotides
mRNAs from this cleavage.from their 5* ends, preferentially at a purine residue. The
resulting capped RNA fragments serve as primers for Previously we demonstrated that the viral P protein
viral mRNA synthesis. ‘‘Cap-snatching’’ has also been complex binds to a specific sequence located near the
considered to be responsible for initiating the observed 5* end of one viral mRNA, M1 mRNA (5). As a result of
degradation of host cell RNA polymerase II transcripts this binding, the P protein complex acquires cap-binding
in the nucleus that occurs during the early phase of virus activity, thereby enhancing the binding of the P complex
infection (4). to the capped M1 mRNA. The binding of the P protein
One of the major questions that has perplexed investi- complex to the 5* end of M1 mRNA regulates the alterna-
gators since the discovery of ‘‘cap-snatching’’ (18 years tive splicing of M1 mRNA. The P protein complex blocks
ago) has concerned the mechanism by which the viral one of the alternative 5* splice sites, the mRNA3 5* splice
site, resulting in the switch to the M2 mRNA 5* splice
site and hence the production of the essential M2 ion
1 Present address: Department of Medical Technology, Chang Gung channel protein. The specific sequence (AGCAAAAGC-
College of Medicine and Technology, 259 Wen-Hwa 1 Road, Kwei- AGG) to which the P protein complex binds is locatedShan, Tao-Yuan, Taiwan, R.O.C.
immediately 3* to the 5* terminal 10–13 nucleotides that2 To whom correspondence and reprint requests should be ad-
dressed. are ‘‘snatched’’ from host cell RNAs during viral mRNA
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efficiencies. Based on these results, we estimated that
approximately 2.4 mg of the viral P protein complex was
needed to bind 1 pmol of either the M1- or the NS1-
specific capped RNA. Previous experiments established
that the binding to M1 mRNA is sequence-specific, be-
cause changing the common AGCAAAAGCAGG se-
quence to UGAUCCAGCAGG (mut.6) reduced binding
about 20-fold (5). In addition, as shown here, the viral P
protein complex did not bind detectably to a short,
capped RNA containing a random sequence derived from
a plasmid (pGEM1) (lanes 10–12). Binding was also de-
pendent on the presence of a 5* terminal methylated cap
structure: when the target RNA contained a GpppG 5*
end rather than a m7GpppGm 5* end, binding of the viral
P protein complex was reduced about 20-fold using ei-
ther the NS1-specific RNA (lanes 7–9) or the M1-specific
FIG. 1. The influenza viral P protein complex binds to the 5* ends of RNA (5) as target.
viral mRNAs in a cap-dependent manner, but does not bind to the 5* To determine whether the binding of the viral P com-
end of nonviral mRNAs. A 58-nucleotide RNA containing the 5*-terminal plex to the 5* end of a viral mRNA protected it against
virus-encoded sequence of the viral M1 mRNA plus an additional 13
cleavage by the viral cap-dependent endonuclease, in-nucleotides 5* to the M1 sequence was synthesized using SP6 RNA
creasing amounts of the viral P protein complex werepolymerase and linearized pGEM1 plasmid DNA containing M1 DNA
as described previously (5). A 58-nucleotide NS1 mRNA-specific RNA bound to a capped viral or nonviral mRNA 5* sequence
was synthesized in the same way. A random sequence (58 nucleotide) that contained 32P only in its 5* terminal methylated cap
RNA was synthesized by T7 polymerase transcription of HindIII-di- structure. These RNAs were then incubated with deter-
gested pGEM1 plasmid. The RNA transcripts were labeled using [a-
gent-treated purified virions, which contain the P protein32P]UTP (sp act: 1000 Ci/mol). RNA with a m7GpppGm 5* end containing
complexes that are associated with virion RNA and thateither a M1 mRNA (lanes 1– 3), NS1 mRNA (lanes 4–6), or random
(pGEM1) (lanes 10–12) 5* sequence (10,000 cpm, 1 pmol of each RNA) catalyze cap-dependent endonucleolytic cleavage and
was incubated with the indicated amounts of the viral P protein complex viral mRNA synthesis (1–3). Nucleoside triphosphates
(3P). The labeled M1 mRNA-specific RNA in lanes 7–9 contained a were omitted from this incubation to block RNA chain
GpppG 5* end. The mixtures were subjected to electrophoresis on a
elongation, thereby confining the reaction to endonucleo-nondenaturing 4% gel to separate the RNA–protein complexes from
lytic cleavage of the added labeled RNA to produce afree (unbound) RNA (5).
capped RNA fragment of approximately 13 nucleo-
tides (2).
As shown in Fig. 2, in the absence of the viral P proteinsynthesis. Because this specific sequence is found in all
the viral mRNAs, we predicted that the P protein complex complex the cap-dependent endonuclease of the virion-
associated transcriptase cleaved each of the capped vi-would bind to this sequence near the 5* ends of all the
viral mRNAs. Therefore, we postulated that this binding ral and nonviral mRNA sequences described above to
produce a capped fragment approximately 13 nucleo-would serve one or more functions that are common to
all the viral mRNAs (5). Here we determined whether one tides long (indicated by the arrow) (Fig. 2A, lanes 2 and
7; Fig. 2B, lane 2; Fig. 2C, lane 2). Consequently, the 5*such common function is the protection of the 5* ends
of all the viral mRNAs from cleavage by the viral cap- ends of viral as well as cellular mRNAs were susceptible
to cleavage. The other capped fragments in these gels,dependent endonuclease.
To establish that the viral P protein complex binds to e.g., the fragment shorter than 13 nucleotides cleaved
from the M1-specific capped RNAs (Fig. 2A) are nonspe-the 5* end of other viral mRNAs in addition to M1 mRNA,
we carried out gel shift experiments using a purified viral cific cleavage products that do not serve as primers for
viral mRNA synthesis (2; present study). Only the 13-P protein complex (Fig. 1). The viral P protein complex
was purified by sucrose density gradient centrifugation nucleotide-long capped fragment is elongated in the
presence of ribonucleoside triphosphates. The additionof nuclear extracts obtained from HeLa cells infected
with three recombinant vaccinia viruses that express the of the viral P protein complex to the wild-type M1-specific
capped RNA (Fig. 2A, lanes 2–6) and to the NS1-specificinfluenza virus PB1, PB2, and PA proteins (5–7). Short
RNAs (58 nucleotides long) corresponding to the 5* ends capped RNA (Fig. 2B) caused a dramatic inhibition of
their endonucleolytic cleavage to produce the specificof M1 and NS1 mRNA (including 13 nucleotides 5* to the
viral-encoded sequence) were used as targets (lanes 1 – 13-nucleotide-long capped fragment. The same results
were obtained using a capped RNA containing the 5*6). Increasing amounts of the viral P protein complex
bound increasing amounts of the M1- and NS1-specific terminal sequence of another viral mRNA, nucleocapsid
mRNA (data not shown). In contrast, the addition of in-capped RNAs. The two RNAs were bound with similar
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FIG. 2. The viral P protein complex protects the 5* end of viral, but not nonviral, mRNAs from cleavage by the viral cap-dependent endonuclease.
Transcripts were synthesized as described in the legend of Fig. 1, but in the absence of labeled UTP. These transcripts were subjected to b-
elimination and then recapped using vaccinia virus guanyl and methyl transferases in the presence of S-adenosylmethionine and [a-32P]GTP (sp
act: 1.44 1 104 Ci/mol) (1, 2). 32P-cap-labeled 58 nucleotide RNA with a m7GpppGm 5* end containing either a wild-type (wt) M1 mRNA (A, lanes
2– 5), mut.6 M1 mRNA (A, lanes 7–10), NS1 mRNA (B, lanes 2–5), or random (pGEM1) (C, lanes 2–5) 5* sequence (10,000 cpm, 0.8 pmol of each
RNA) was incubated with the indicated amounts of the viral P protein complex (3P) at 207 for 15 min. Detergent-treated purified influenza virus (3
mg of protein) was added, and the mixture was incubated at 317 for 60 min in the absence of ribonucleoside triphosphates. As a control, neither
the viral P protein complex (3P) nor the detergent-treated virus was added to an equivalent aliquot of each of the substrates (A, lanes 1 and 6; B,
lane 1; C, lane 1). RNA was extracted and analyzed by electrophoresis on 20% denaturing gels. The arrows denote the specific capped fragment
of approximately 13 nucleotides cleaved from each of the substrates by the viral cap-dependent endonuclease. Because the gels for A, B, and C
were run as separate experiments, the 13-nucleotide capped fragment did not necessarily migrate to the same position in the gels of these three
panels. The molecular weight marker for the 13-nucleotide-long capped fragment was the fragment of this size produced by endonucleolytic cleavage
of alfalfa mosaic virus RNA 4, a fragment which has been identified and characterized previously (2).
creasing amounts of the viral P protein complex did not inhibition can be attributed to the residual, low level bind-
ing of the viral P protein complex to the mut.6 M1-specificinhibit the endonucleolytic cleavage of the capped RNA
containing a random sequence at its 5* end (pGEM1) capped RNA that occurs at higher levels of the P protein
complex (5). Based on these results, we estimated that(Fig. 2C). In addition, the mutations (mut.6) at the 5* end
of the M1-specific capped RNA that severely reduced approximately 2.5 mg of the viral P protein complex was
needed to protect 1 pmol of either the M1- or NS1-spe-binding of the viral P protein complex almost totally elimi-
nated the ability of the P protein complex to protect this cific RNA from endonucleolytic cleavage. This is essen-
tially the same amount of the viral P protein complexmutated M1-capped RNA from endonucleolytic cleavage
(Fig. 2A, lanes 7–10). needed to bind 1 pmol of either of these RNAs (see
above). These results establish that the inhibition of en-These endonuclease results are quantitated in Fig. 3.
In the presence of 0.50 mg of the viral P protein complex, donucleolytic cleavage of a mRNA was dependent on
the binding of the viral P protein complex to a specificthe endonucleolytic cleavage of the M1- and NS1-spe-
cific capped RNAs was inhibited approximately 50%, sequence that is located near the 5* end of viral, but not
nonviral, mRNAs.whereas there was no effect on the cleavage of either
the mut.6 M1-specific capped RNA or the pGEM1-capped Our results establish that the complex of the three
influenza viral P proteins carries out two disparate, op-RNA. Increasing the amount of the viral P protein com-
plex to 1.0 mg increased the inhibition of the cleavage of posing functions: the endonucleolytic cleavage of all
capped mRNAs and the selective protection of viralthe M1- and NS1-specific capped RNAs to greater than
90%. The cleavage of the pGEM1-capped RNA was still mRNAs, but not cellular mRNAs, against this cleavage.
The acquisition of these two very different functionsnot inhibited, and the cleavage of the mut.6 M1-specific
capped RNA was only slightly (20%) inhibited. This slight stems from the fact that the complex of the three P pro-
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copying of template RNAs into virion RNAs. This binding
is not shown in Fig. 4.
The overwhelming majority of the positive strand RNAs
in infected cells are the viral mRNAs (3), almost all of
which, as previously documented (9, 10), contain the
AGCAAAAGCAGG sequence immediately 3* to the 5*
terminal sequence that is ‘‘snatched’’ from host cell RNAs.
If this binding occurs, then, as shown here, the viral P
protein complex is destined to protect each of the viral
mRNAs from cleavage by the viral endonuclease (Fig. 4),
as well as to regulate the alternative splicing of one of
the viral mRNAs, M1 mRNA (5). Binding to this sequence
in viral mRNA also activates cap-binding activity, thereby
enhancing the binding of the viral P protein complex to
the capped viral mRNAs (5; present study). As a conse-
quence, the viral P protein complex is bound to viralFIG. 3. Quantitation of the selective protection of the 5* ends of viral,
and not nonviral, mRNAs by the viral P protein complexes against mRNA at two positions, the cap and the common AGC-
cleavage by the viral cap-dependent endonuclease. For each capped AAAAGCAGG sequence. This would be expected to in-
RNA substrate shown in Fig. 2, the relative amounts of the specific 13- crease the ability of this viral P protein complex to block
nucleotide-long, capped fragment that were produced in the presence
access of the viral mRNA to the viral cap-dependent en-of different amounts of the viral P protein complexes were determined
donuclease that is composed of a viral P protein complexby densitometry of the X-ray film of the gels. The relative amounts were
converted to percentages of the control, which is the amount of the that is bound to both the 5* and 3* sequences of virion
capped fragment that was produced from the same substrate in the RNA. Because the latter P protein complex is already
absence of the viral P protein complexes. bound to the 5* AGUAGAAACAAG sequence of virion
RNA, it would likely be able to compete only for binding to
the cap of viral mRNA and not for binding to the common
teins lacks any detectable activity in the absence of spe- AGCAAAAGCAGG sequence near the 5* end of viral
cific RNA sequences (6, 7). The viral P protein complex mRNA. Finally, it should be noted that the 3* end of influ-
can bind initially to either of two specific RNA sequences, enza viral mRNA lacks a copy of the 5* end of the virion
and the sequence that is chosen determines the ultimate RNA template because transcription during viral mRNA
function of the viral P protein complex (Fig. 4). One synthesis terminates 17–22 nucleotides before the 5*
choice, which was elucidated by Krystal and coworkers end of virion RNA is reached (3). Consequently, viral
(6–8), is the AGUAGAAACAAG sequence that is found mRNA lacks a 3* terminal sequence that might be suffi-
at the 5* terminus of each of the eight influenza virion ciently similar to the 3* terminal sequence of virion RNA
(negative strand) RNAs. If the viral P protein complex to activate the endonuclease activity of the viral P protein
binds to this sequence, then the viral P complex is des- complex.
tined to become a functional transcriptase enzyme (6– In contrast to viral mRNAs, the 5* ends of host cell
8). This initial binding causes the P protein complex to mRNAs are not protected by the sequence-specific viral
acquire one activity, namely cap-binding activity, but P protein complex and hence are efficiently cleaved by
does not activate endonucleolytic activity. In order to ac- the viral endonuclease. It should, however, be noted that
quire the latter activity, as well as transcriptase activity, the caps of cellular mRNAs in the nucleus are associated
it is necessary for the viral P protein to bind subsequently with two cellular cap-binding proteins, CBP20 and CBP80
to another RNA sequence, the 3* terminal common se- (11, 12). Presumably, these two cellular proteins do not
quence of the virion RNAs. interfere with, and are likely displaced by, the viral cap-
The other choice for the viral P protein complex is to dependent endonuclease.
bind to the AGCAAAAGCAGG sequence that is found in Influenza virus-infected cells have been shown to con-
the two types of positive strand, virus-specific RNAs that tain two populations of viral P protein complexes (13).
are synthesized in infected cells (7, 8; present study). It One population, which is associated with viral nucleo-
should be noted that this sequence differs from the com- capsids containing virion RNA molecules, undoubtedly
mon AGUAGAAACAAG 5* sequence in virion RNAs at 4 consists of the viral P protein complexes that are bound
of the 12 positions. The minority of the positive strand to the 5* and 3* ends of virion RNAs and that catalyze
RNAs are the template RNAs, i.e., the full-length copies cap-dependent cleavage of host mRNAs and viral mRNA
of each of the virion RNAs (3). If the viral P protein com- synthesis. The second population of viral P protein com-
plex binds to the AGCAAAAGCAGG sequence found at plexes, which is found predominantly in the nucleus, is
the 5* terminus of the template RNAs, then the viral P not associated with viral nucleocapsids. This population
contains the vast majority of the viral P protein complexesprotein complex will presumably function to catalyze the
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FIG. 4. The influenza viral P protein complex carries out two disparate, opposing functions: the endonucleolytic cleavage of all capped mRNAs;
and the selective protection of viral mRNAs, but not cellular mRNAs, against this cleavage. The viral P protein complex lacks any detectable activity
in the absence of a specific RNA sequence. One specific RNA sequence to which it binds is the 5* terminal AGUAGAAACAAG sequence present
on all eight virion RNA segments (6–8). As a result of this binding, the viral P protein complex acquires cap-binding activity. Subsequent binding
of the 3* end of the virion RNA results in the acquisition of cap-dependent endonuclease and transcriptase activities. The other specific sequence
to which it binds is the AGCAAAAGCAGG sequence that is found both in viral template RNAs, where it is located at the 5* ends (not shown), and
in viral mRNAs, where it is located immediately 3* to the 5* sequence ‘‘snatched’’ from host cell-capped RNAs (shown). As a result of the latter
binding, the 5* ends of viral mRNAs are protected against cleavage by the viral cap-dependent endonuclease. In contrast, the 5* ends of host cell
mRNAs are not protected and are cleaved by the viral endonuclease.
that are present in the infected cell. It is therefore reason- cellular pre-mRNAs and in the nuclear export of cellular
capped RNAs has been reported to be mediated by theable to propose that it is these viral P protein complexes
that bind to the 5* ends of viral mRNAs in the nucleus, complex of the CBP20 and CBP80 cap-binding proteins
(11, 12). However, splicing and nuclear export of influ-thereby protecting the viral mRNAs from cleavage by
the viral cap-dependent endonuclease. In addition, these enza viral mRNAs almost certainly occurs under condi-
tions in which the viral P protein complex has replacedviral P protein complexes would be expected to bind to
the 5* ends of both virion RNAs and template RNAs to the CBP20–CBP80 cap-binding complex at the 5* ends
of the viral mRNAs. This suggests that the viral P proteincatalyze transcription and replication. According to this
hypothesis, the amount of these viral P protein com- complex can substitute for the CBP20–CBP80 complex
in these two RNA processing steps. In fact, we haveplexes in the nucleus would be sufficient to bind to most,
or all, of these three virus-specific RNAs. already shown that the efficiency of splicing of influenza
viral M1 mRNA in vitro is not reduced when its 5* end isOur results indicate that the 5* ends of influenza viral
mRNAs located in the nuclei of infected cells should be bound to the viral P protein complex (5, 14). Second, the
CBP20–CBP80 complex is associated with the 5* endsbound to viral P protein complexes at two sites, the 5*
terminal cap and the common AGCAAAAGCAGG se- of cellular mRNAs only in the nucleus. In the cytoplasm
the translation initiation factor eIF-4E binds to the cap ofquence that begins 10– 13 nucleotides from the cap. It
would be expected that this binding of the viral P protein cellular mRNAs (15, 16). Is the viral P protein complex
associated with viral mRNAs only in the nucleus or doescomplex would prevent the binding of the two cellular
cap-binding proteins, CBP20 and CBP80 (11, 12), to the it remain associated with the viral mRNAs after they are
transported to the cytoplasm?caps of viral mRNAs. This raises several intriguing is-
sues. First, the role of the cap structure in the splicing of The influenza virus P protein complex is a dramatic
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